With $20.7 Million Series A Cash, RaNA Seeks To Be A Groundbreaker In Long Non-Coding RNA Therapeutics
This article was originally published in The Pink Sheet Daily
Biotech hopes to begin IND-enabling studies in 2013 and bring first candidate into the clinic in 2014 in a new field it believes will have applicability in numerous therapeutic areas.
You may also be interested in...
Alnylam will license its IP estate to agriculture giant Monsanto over 10 years, in turn getting a $29.2 million upfront payment that it will put toward further development of RNAi therapeutics.
Biopharma start-ups raised $338.1 million – 51% less than in Q4 2011. Device companies brought in $123.7 million and diagnostics firms raised $99.3 million; Series C rounds generated more money in both the device and diagnostic sectors than any other financing type. Cancer was the most prevalent therapeutic area for biopharma alliances. During Q1, M&As across biopharma and diagnostic industries were valued at a total of $471 million.
Plus news on recent financings by Neurocrine Biosciences, Prosensa, RaNA Therapeutics and Trius Therapeutics.